Anemia, hypochromic microcytic with iron overload

Summary

Anemia, hypochromic microcytic with iron overload (MONDO:0000104) is a disease. A subtype of hypochromic microcytic anemia — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	anemia, hypochromic microcytic with iron overload
Mondo ID	MONDO:0000104
MeSH	C567144
OMIM	206100
UMLS	C2673913
MedGen	388759
GARD	0022710
Is cancer (heuristic)	no

Also known as: anemia, hypochromic microcytic, with iron overload

Disease family

This is a subtype of hypochromic microcytic anemia. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › hematologic disorder › anemia › microcytic anemia › hypochromic microcytic anemia › anemia, hypochromic microcytic with iron overload

Related subtypes (1): iron deficiency anemia

Subtypes (2): microcytic anemia with liver iron overload, severe congenital hypochromic anemia with ringed sideroblasts

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.